Period pain needs innovation
1.8 billion people menstruate every month
1.4 billion experience pain with their periods
38% of menstruating women report pain so severe that it disrupts activities of daily life
Meliodays is a pharmaceutical company developing a first-in-class intrauterine device with the potential to transform how period pain can be managed. Our prototype is currently advancing with nonclinical development.
No hormones.
No cycle disruption.
Reduced systemic exposure.
MelioOne® is being developed as the first intrauterine device for relief of period pain. It uses a slow-release mechanism to deliver a low, sustained dose of an established pain medicine locally over two years, approximately equivalent to one 400 mg tablet, spread out gradually to reduce systemic exposure.
MelioOne® is classified as a combination product: a medical device paired with a pharmacological agent. This dual classification means our product advancement follows stringent regulatory frameworks, an approach designed to build the foundations for trust and long-term safety as development progresses.
Latest News, Product Developments and Corporate Updates
23.06.202618.12.202518.11.202529.07.202520.03.2025